Abstract:Gliomas are primary malignancies of the brain. Tumors are staged based on malignancy, nuclear atypia, and infiltration of the surrounding brain parenchyma. Tumors are often diagnosed once patients become symptomatic, at which time the lesion is sizable. Glioblastoma (grade IV glioma) is highly aggressive and difficult to treat. Most tumors are diagnosed de novo. The gold standard of therapy, implemented over a decade ago, consists of fractionated radiotherapy and temozolomide, but unfortunately, chemotherapeutic resistance arises. Recurrence is common after initial therapy. The tumor microenvironment plays a large role in cancer progression and its manipulation can repress progression. The advent and implementation of immunotherapy, via manipulation and activation of cytotoxic T cells, have had an outstanding impact on reducing morbidity and mortality associated with peripheral cancers under certain clinical circumstances. An arsenal of immunotherapeutics is currently under clinical investigation for safety and efficacy in the treatment of newly diagnosed and recurrent high grade gliomas. These immunotherapeutics encompass antibody-drug conjugates, autologous infusions of modified chimeric antigen receptor expressing T cells, peptide vaccines, autologous dendritic cell vaccines, immunostimulatory viruses, oncolytic viruses, checkpoint blockade inhibitors, and drugs which alter the behavior of innate immune cells. Effort is focusing on determining which patient populations will benefit the most from these treatments and why. Research addressing synergism between treatment options is gaining attention. While advances in the treatment of glioma stagnated in the past, we may see a considerable evolution in the management of the disease in the upcoming years.

Advances in the study of tumor suppressor genes in gliomas

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

[Advance of Molecular Subtyping and Precise Treatment for Gliomas].

Advances in glioma therapy and its animal models

The Pathobiology of Glioma Tumors

Recent Advances in the Radiotherapy of Gliomas

Advance of Immune Checkpoint Inhibitors and Clinical Trials in Glioma

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

The Relationship between TGF-β Signal Pathway and Tumor Cells' Biological Characteristics in Glioma

Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas

CNS Germ Cell Tumors: Molecular Advances, Significance in Risk Stratification and Future Directions

The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential

Molecular pathways in the formation of gliomas

Progress and prospect in tumor treating fields treatment of glioblastoma

Advances in immunotherapeutic research for glioma therapy

Research Progress in Immunotherapy of Gliomas

The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness.

Progress in Glioma Tumor Markers

Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy

Deciphering the CNS-glioma dialogue: Advanced insights into CNS-glioma communication pathways and their therapeutic potential

Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy